25Dec 2023
Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes

Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes

In the Netherlands, the routine use of neoadjuvant short-course radiotherapy for nonlocally advanced rectal cancer has decreased by 50% from 2011 to 2016. A study involving 3,152 patients revealed that the 2016 cohort, with selective radiotherapy application, showed no compromise in cancer-related outcomes. The 4-year overall survival was significantly higher at 86.4%, compared to 79.6% in 2011, indicating safe treatment de-intensification without impacting efficacy. The study underscores the importance of optimizing clinical staging and surgery for nonlocally advanced rectal cancer after the Dutch total mesorectal excision trial.

  • #oncology

Like

Save

Share